We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Submitted, not yet approved
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
Repair of Ruptured Brain Aneurysms with a Novel Stent Device and Oral Aspirin
Scientific title
Repair of Ruptured Intracranial Aneurysms Using the Pipeline Shield with Aspirin Monotherapy: A Multicentre, Prospective, Single-Arm Clinical Trial
Secondary ID [1] 296269 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ruptured intracranial aneurysm 309946 0
Condition category
Condition code
Stroke 308720 308720 0 0

Study type
Description of intervention(s) / exposure
The intervention will consist of endovascular delivery one or more Pipeline-Shield devices to treat patients with this particular subset of difficult aneurysms using aspirin as the sole antiplatelet agent. This will be done by experienced (CCINR-certified) interventional neuroradiologists. The procedure will be a once-only intervention, with follow up on imaging studies using a combination of MRI and angiography. Clinical follow up will also be obtained. The follow up period for this trial will be 6 months.

Aspirin will be administered as a 500mg intravenous dose during the procedure and continued orally or via nasogastric administration post procedurally, depending on the patients' level of consciousness at a dose of 100-300mg daily in single or divided dose. Compliance will be monitored during the inpatient period by medication charts, and during the outpatient phase by regular follow up phone calls with patients/carers and at gazetted clinical face-to-face meetings.
Intervention code [1] 312606 0
Treatment: Devices
Comparator / control treatment
No control group
Control group

Primary outcome [1] 307700 0
Stent patency (short term)

This will be assessed between days 5-15 with digital subtraction angiography.
Timepoint [1] 307700 0
5-15 days post treatment.

This timepoint varies from patient to patient and will only be assessed at a single timepoint within these days unless further angiography is required on clinical grounds.
Secondary outcome [1] 352570 0
Aneurysm occlusion (short term)
Timepoint [1] 352570 0
Day 5-15. Patients with this condition will require at least one digital subtraction angiogram during their admission in the 5-15 day window. This varies from patient to patient depending on their clinical need. The trial merely stipulates that at least one DSA should be done in this window.
Secondary outcome [2] 352571 0
Aneurysm occlusion (long term)
Day 5-15 DSA (as per above)
MRI at day 60 post treatment
DSA at 6 months
Timepoint [2] 352571 0
180 days post treatment
Secondary outcome [3] 352572 0
Stent patency (long term)
MRI at day 60 post treatment
DSA at 6 months
Timepoint [3] 352572 0
60 and 180 days post treatment
Secondary outcome [4] 352574 0
New cerebral ischaemia
MRI within 72 hours of treatment
MRI at day 60 post treatment
Timepoint [4] 352574 0
Within 72 hours of treatment and at 60 days post treatment
Secondary outcome [5] 352575 0
Haemorrhagic complications

These will be assessed based on clinical evaluation since they are usually symptomatic. Occasionally, silent haemorrhagic changes can be seen on MRI (therefore possibly visible on MRI scans as above).

Examples would include:
Intracerebral haemorrhage
Aneurysm rebleeding
Gastrointestinal bleeding
Excessive bruising
Timepoint [5] 352575 0
Any haemorrhagic complication up to 180 days post treatment.

Key inclusion criteria
• 18 years or older
• Ruptured intradural aneurysm with morphology not amenable to conventional open or
endovascular repair
• Ruptured intracranial aneurysm unsuitable for open repair, requiring stent support for
endovascular therapy (EVT), but with contraindication to dual antiplatelet therapy, for
o Requirement for immediate ventricular drainage
o Requirement for urgent craniotomy and haematoma evacuation
o Requirement for tracheostomy or other major surgical procedure
o Allergy to clopidogrel, prasugrel
• Criteria above to be evaluated by consultation between the duty open and endovascular
consultants at the participating centre.
• Verbal and written consent from patient and/or next of kin
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
• All ruptured aneurysms where conventional open neurosurgical and endovascular repair
techniques are deemed feasible by the open and endovascular consultant on duty
• Inability to obtain consent from patient or guardian/next of kin
• Contraindication or allergy to aspirin
Age <18 years

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 12108 0
Prince of Wales Hospital - Randwick
Recruitment hospital [2] 12109 0
Liverpool Hospital - Liverpool
Recruitment hospital [3] 12110 0
Gold Coast University Hospital - Southport
Recruitment postcode(s) [1] 24276 0
2031 - Randwick
Recruitment postcode(s) [2] 24277 0
2170 - Liverpool
Recruitment postcode(s) [3] 24278 0
4215 - Southport

Funding & Sponsors
Funding source category [1] 300862 0
Commercial sector/Industry
Name [1] 300862 0
Address [1] 300862 0
2 Alma Road
Macquarie Park NSW 2113
Country [1] 300862 0
Primary sponsor type
Dr Jason Wenderoth
Institute of Neurosciences
Level 2
High Street Building
Prince of Wales Hospital
Randwick NSW 2031
Secondary sponsor category [1] 300418 0
Name [1] 300418 0
Address [1] 300418 0
Country [1] 300418 0
Other collaborator category [1] 280383 0
Name [1] 280383 0
Dr Nathan Manning
Address [1] 280383 0
Department of Interventional Neuroradiology
Liverpool Hospital
Elizabeth Street
Liverpool NSW 2170
Country [1] 280383 0
Other collaborator category [2] 280384 0
Name [2] 280384 0
Dr Hal Rice
Address [2] 280384 0
Interventional Neuroradiology Department
Gold Coast University Hospital
1 Hospital Blvd
Southport QLD 4215
Country [2] 280384 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 301637 0
South East Sydney Local Health District HREC
Ethics committee address [1] 301637 0
Prince of Wales Hospital
High Street
Randwick NSW 2031
Ethics committee country [1] 301637 0
Date submitted for ethics approval [1] 301637 0
Approval date [1] 301637 0
Ethics approval number [1] 301637 0

Brief summary
Some brain aneurysms, when they bleed, are difficult or impossible to treat safely with "conventional" techniques.

There is a device similar to a stent which has been used for 10 years to repair some aneurysms, called the Pipeline Embolisation Device, which has previously needed aspirin plus a stronger blood thinner before inserting it to prevent the device clotting and causing a stroke.

The latest version of this device Pipeline-Shield), in use in Australia for 3 years now, has a coating which mimics the lining of blood vessels. This means that the stronger blood thinner may not be required to keep the device from clotting.

We have been using the Pipeline-Shield with aspirin only to treat some patients with these "impossible" aneurysms under compassionate use for 2 years with very promising results.

We hypothesise that using the device in this manner with aspirin only is safe, and that the device will clot only very rarely if used in this manner.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 87618 0
Dr Jason Wenderoth
Address 87618 0
Institute of Neurosciences
Prince of Wales Hospital
Level 2
High Street
Randwick NSW 2031
Country 87618 0
Phone 87618 0
+61 2 9382 1111
Fax 87618 0
Email 87618 0
Contact person for public queries
Name 87619 0
Dr Jason Wenderoth
Address 87619 0
Institute of Neurosciences
Prince of Wales Hospital
Level 2
High Street
Randwick NSW 2031
Country 87619 0
Phone 87619 0
+61 2 9382 1111
Fax 87619 0
Email 87619 0
Contact person for scientific queries
Name 87620 0
Dr Jason Wenderoth
Address 87620 0
Institute of Neurosciences
Prince of Wales Hospital
Level 2
High Street
Randwick NSW 2031
Country 87620 0
Phone 87620 0
+61 2 9382 1111
Fax 87620 0
Email 87620 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
Protect patient privacy
What supporting documents are/will be available?
No other documents available
Summary results
No Results